Top 5 Healthcare Technology Companies To Invest In Right Now

Heavy trading and a run-up in the share price of Investors Capital Holdings Ltd., the parent company of independent broker-dealer Investors Capital Corp., is fueling speculation that the firm has become an acquisition target.

Last Thursday saw an intense spike in its trading volume, with 434,100 shares changing hands and the price of the stock briefly reaching $8.90 per share, its 52-week high.

The typical daily trading volume this year has been closer 13,000 shares, according to Yahoo! Finance. Shares traded at $4.05 as recently as Aug. 30. Its low for the year is $2.96 per share.

Top 5 Healthcare Technology Companies To Invest In Right Now: Ruby Tuesday Inc.(RT)

Ruby Tuesday, Inc., together with its subsidiaries, develops, operates, and franchises casual dining restaurants in the United States, Puerto Rico, Guam, and internationally. The company operates its restaurants under the Ruby Tuesday brand, as well as owns and operates one Marlin & Ray?s, one Truffles, and two Wok Hay casual dining restaurants. As of August 30, 2011, it owned and operated 746 Ruby Tuesday restaurants; and 43 domestic and 52 international franchisees operated restaurants. The company was founded in 1920 and is based in Maryville, Tennessee.

Advisors’ Opinion:

  • [By James Brumley]

    Filing chapter 11 would help Quiznos with its $570 million in debt (compared to about $600 million in sales for 2012), though less debt still doesn’t solve the bigger problem for this group of approximately 2000 restaurants — a waning number of customers.

    Ruby Tuesday (RT)

    Not that Ruby Tuesday (RT) was ever really lighting it up on the revenue or earnings front, but the past three quarters’ revenue has been so weak, the company slid from breakeven levels to sizeable losses … with no end in sight for its restaurants.

  • [By Rick Aristotle Munarriz]

    AP/Shiho FukadaActivist investor Carl Icahn loves to give advice to public companies. But this week, his advice for eBay felt a couple of years behind the curve. Companies can make brilliant moves, but there are also times when things don’t work out quite as planned. From a classy handbag maker carrying its latest financials to market, to a blowout report by the leading streaming video service, here’s a rundown of the week’s best and worst in the business world. Netflix (NFLX) — Winner Netflix was last year’s top performer among S&P 500 stocks, and it’s off to another strong start in 2014. Shares of the leading video service hit another all-time high this week after it posted blowout quarterly results. Netflix closed out the year on a strong note with more than 44 million streaming subscribers worldwide and expanding profit margins. It expects to top 48 million streaming members by the end of March. Strong financial results naturally make you a winner, but Netflix also got the market excited by announcing that it will soon offer a variety of pricing plans. More importantly, it’s suggesting that it may eventually increase the price of its basic $7.99 a month plan. Coach (COH) — Loser Luxury handbags are still selling, but Coach totes aren’t faring as well. The iconic maker of high-end purses and accessories posted disappointing quarterly results on Tuesday. Sales declined by 6 percent during the seasonally potent holiday quarter, and net income took an even bigger hit. Foreign currency translations weighed on the results, but sales still would have been lower if there weren’t any currency fluctuations. Coach investors shouldn’t be surprised. Sales, net income, and store-level comparable sales also slipped three months earlier. It’s not the niche. Michael Kors (KORS) has been able to post healthy double-digit growth through the gradual fade in prominence at Coach. Beats Music — Winner Music streaming has become popular, and that’s big for the musi

  • [By Rick Aristotle Munarriz]

    Brinker International Casual dining stocks aren’t dead as an investment category. Investors just need to know where the tasty treats can be found on the menu. Chili’s Grill & Bar parent Brinker International (EAT) moved higher on Wednesday after reporting better than expected quarterly results. Company sales climbed higher, fueled by a 0.3 percent increase in comparable-restaurant sales. Its international locations fared even better. Some casual dining chains that are bucking the general downward trend and posting positive comps are doing so by discounting aggressively to keep patrons coming. But that’s not Chili’s game at all. Net margins actually expanded nicely at Brinker, with adjusted earnings per share climbing 18 percent during its fiscal second quarter. The 1,557-unit Chili’s chain is doing just fine. But the same can’t be said about its competition. Red Ink, Ruby Ink Seeing shares of Brinker open 8 percent higher after posting better than expected quarterly results may be painful for investors in Ruby Tuesday (RT) or Red Lobster parent Darden Restaurants (DRI). Those two stocks took a hit the last time they offered up fresh financials. Ruby Tuesday and Red Lobster are falling out of favor with the hungry, with comps plunging 7.8 percent and 4.5 percent respectively in their latest quarters. Both companies have fallen short of Wall Street profit targets in each of their past three quarters. Brinker, on the other hand, has now surpassed bottom-line expectations in three of the past four quarters. With Ruby Tuesday’s profits turning to losses and Darden so disillusioned with Red Lobster that it’s looking to sell it or spin it off, it’s easy to see why savvy investors looking at the casual dining sector are turning to Brinker. The stock hit a new 52-week high on Wednesday, and this could be just the beginning. Tech is the Secret Ingredient Why is Chili’s succeeding at a time when profits at many of its peers are receding? Barron’s argued earl

Top 5 Healthcare Technology Companies To Invest In Right Now: ENGlobal Corporation (ENG)

ENGlobal Corporation provides engineering and professional services principally to the energy sector in the United States and internationally. It operates in two segments, Engineering and Construction, and Automation. The Engineering and Construction segment offers services relating to the development, management, and execution of projects requiring professional engineering and related project services primarily to the midstream and downstream sectors of the oil and gas industry, as well as to chemical and petrochemical manufacturers, utilities, and alternative energy developers. Its services include conceptual studies, project definition, cost estimating, engineering design, environmental compliance, material procurement, project management, facility inspection, and construction management. This segment also provides engineering, design, electrical and instrument installation, and operation and maintenance services for facilities to government, public sector, and internat ional facilities. The Automation segment offers services related to the design, fabrication, and implementation of process distributed control and analyzer systems, advanced automation, information technology, and heat tracing projects primarily to the upstream and downstream sectors. This segment also designs, assembles, integrates, and services control and instrumentation systems for specific applications in energy and processing related industries. ENGlobal Corporation was founded in 1985 and is headquartered in Houston, Texas.

Advisors’ Opinion:

  • [By Roberto Pedone]

     

    ENGlobal (ENG) provides engineering and professional services principally to the energy sector in the U.S. and internationally. This stock closed up 9% to $1.60 in Thursday’s trading session.

     

    Thursday’s Range: $1.48-$1.63

    52-Week Range: $0.30-$1.88

    Thursday’s Volume: 245,000

    Three-Month Average Volume: 59,090

     

    From a technical perspective, ENG spiked sharply higher here back above its 50-day moving average of $1.50 with above-average volume. This move pushed shares of ENG into breakout territory, since the stock took out some near-term overhead resistance at $1.59. Shares of ENG are now starting to move within range of triggering another near-term breakout trade. That trade will hit if ENG manages to take out some near-term overhead resistance levels at $1.66 to $1.71 with high volume.

     

    Traders should now look for long-biased trades in ENG as long as it’s trending above Thursday’s low of $1.48 or above more support at $1.40 and then once it sustains a move or close above those breakout levels with volume that hits near or above 59,090 shares. If that breakout hits soon, then ENG will set up to re-test or possibly take out its 52-week high at $1.88. Any high-volume move above that level will then give ENG a chance to tag $2 to $2.20.

     

  • [By GURUFOCUS]

    The Rise and Fall of Tontine Asset Management and ENGlobal (ENG)

    Gendell rarely conducted interviews, almost never publicizing his stock selections or his theories in regard to investing. The average investor had never heard of him or his hedge fund; however anyone who tracked money managers closely, was well aware the outstanding returns which were flowing into the pockets of the clients at Tontine. In 2003 and 2004, Gendell recorded near miraculous gains, approximately doubling the value of his portfolios, in back to back years.

Top 5 Healthcare Technology Companies To Invest In Right Now: Phillips-Van Heusen Corporation(PVH)

PVH Corp. designs and markets branded dress shirts, neckwear, sportswear, footwear, and other related products worldwide. The company?s Calvin Klein Licensing segment licenses Calvin Klein Collection, ck Calvin Klein, and Calvin Klein brands for sportswear, jeanswear, underwear, fragrances, eyewear, men?s tailored clothing, women?s suits and dresses, hosiery, socks, footwear, swimwear, jewelry, watches, outerwear, handbags, leather goods, home furnishings, and accessories; and to operate retail stores. Its Wholesale Dress Furnishings segment markets dress shirts and neckwear principally under the ARROW, Calvin Klein, ck Calvin Klein, Calvin Klein Collection, IZOD, Eagle, Sean John, Donald J. Trump Signature Collection, Kenneth Cole New York, Kenneth Cole Reaction, JOE Joseph Abboud, DKNY, Tommy Hilfiger, Elie Tahari, J. Garcia, and MICHAEL Michael Kors brands. The company?s Wholesale Sportswear and Related Products segment offers sportswear, including men?s knit and w oven sport shirts, sweaters, bottoms, swimwear, boxers, and outerwear principally under the IZOD, Van Heusen, ARROW, Geoffrey Beene, Timberland, and Calvin Klein brands; and women?s sportswear, including knit and woven sport shirts, sweaters, bottoms, and outerwear under the IZOD brand. Its Retail Apparel and Related Products segment provides men?s dress shirts; neckwear and underwear; men?s and women?s suit separates; men?s and women?s sportswear, including woven and knit shirts, sweaters, bottoms, and outerwear; men?s and women?s accessories; sportswear; and men?s fragrance. The company?s Retail Footwear and Related Products segment offers casual and dress shoes for men, women, and children; and apparel and accessories. The company was formerly known as Phillips-Van Heusen Corporation and changed its name to PVH Corp. in June, 2011. The company was founded in 1881 and is headquartered in New York, New York.

Advisors’ Opinion:

  • [By John Kell var popups = dojo.query(“.socialByline .popC”); popups.forEach(func]

    PVH Corp.(PVH) swung to a loss in the fiscal fourth quarter as the clothing company faced charges tied to its acquisition of Warnaco Group Inc., a deal that helped boost revenue. Adjusted earnings topped the company’s own forecast. Shares edged up 2.8% to $120.50 premarket.

  • [By Ben Levisohn]

    Stocks have tumbled after a slightly stronger open as Visa (V), American Express (AXP), United Technologies (UTX), Noble Corp (NE) and PVH Corp. (PVH) slide.

Top 5 Healthcare Technology Companies To Invest In Right Now: Emergent Biosolutions Inc. (EBS)

Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company’s development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, ba sed on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.

Advisors’ Opinion:

  • [By Stephen Quickel]

    Emergent BioSolutions (EBS) is a far smaller specialist in bio-medical products for the military and commercial markets, including anthrax vaccine and decontamination agents. With revenues nearing $400 million, EBS is acquiring Canada’s Cangene Corp. to expand its product line.

  • [By Traders Reserve]

    I discovered Emergent Bio Solutions (EBS) when I ran my proprietary P/E Gap model at the end of December. Without getting into the details, P/E Gap identifies stocks that have the potential to rally based on being significantly undervalued.

Top 5 Healthcare Technology Companies To Invest In Right Now: Synergy Pharmaceuticals Inc (SGYP)

Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company’s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company’s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.

As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. A s of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.

The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.

Advisors’ Opinion:

  • [By Monica Gerson]

    Breaking news

    Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable’s quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company’s board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.

    Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

  • [By Sean Williams]

    Finally, Synergy Pharmaceuticals (NASDAQ: SGYP  ) may have had the wildest week of them all. Synergy’s share price spiked 16% on Tuesday as an analyst at Cantor Fitzgerald raised her peak sales estimate for plecanatide, the company’s midstage drug for chronic idiopathic constipation and irritable bowel syndrome with constipation, to $1.58 billion from $1.05 billion, as clinical data has been stronger than expected. However, the company didn’t return the favor to shareholders by — the very next day, mind you – announcing a secondary offering of 16.375 million shares. The downside of clinical-stage companies is the always apparent risk of dilution. Shares have lost 25% since their Tuesday close.